FDA Approves New Use for Daratumumab in Multiple Myeloma

The FDA has approved daratumumab, in combination with either of two other standard therapies, in patients with multiple myeloma whose disease has progressed after only a single prior treatment course.

Cancer Currents: An NCI Cancer Research Blog